/ /

  • linkedin
  • Increase Font
  • Sharebar

    Tracking the best treatment for fungal keratitis

    Studies favor natamycin, but more high-quality research needed on antifungal agents

    Take-home message: Natamycin appears to be the best treatment for fungal keratitis, whereas voriconazole is less effective and associated with more adverse effects.




    Hyderabad, India—Looking for the best treatment for fungal keratitis?

    Available data show that natamycin appears to be the best antifungal agent against molds and yeast, said Prashant Garg, MD, LV Prasad Eye Institute, Hyderabad, India.

    However, Dr. Garg is also quick to point out that the rigor of research on fungal keratitis has been suboptimal and that ophthalmologists need more high-quality studies exploring more molecules.

    Dr. Garg and colleagues reviewed the literature for both animal and human clinical trials, as well as lab-based studies.

    A variety of antifungal agents are used for fungal keratitis—including polyenes, imadazoles, econazoles, and triazoles—as well as antiseptic agents, including chlorhexidine, povidone iodine, and silver sulfadiazine.

    In addition, there has been interest in newer azoles and echinocandins because of their unique mechanism of action, Dr. Garg said.

    The various treatments have been used for topical monotherapy, in combination with systemic antifungal therapy, and in subconjunctival or intracorneal therapy.

    The research on the best therapy for fungal keratitis does not match the diversity of treatment options available.

    “We were surprised to find that most reports were in the form of case reports sharing individual experience,” Dr. Garg said.

    There was paucity of comparative trials, and in the ones that do exist, only a few agents were tested.

    The best evidence found so far has been a Cochrane meta-analysis that included 12 trials, 981 subjects, and eight different antifungal agents, Dr. Garg said.1

    The authors had a primary outcome of a clinical cure in 2 months and secondary features such as time to clinical cure, best spectacle-corrected visual acuity, rate of adverse reactions, and quality of life.

    “The authors concluded that there was a wide variety of quality in these studies and that most [of the studies] were underpowered and provided no good evidence for most pathogens,” Dr. Garg said.

    The authors wrote that natamycin seemed to be more effective than voriconazole.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results